NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

Home・Aktien・Lonza Group AG

Lonza Group AG

Open

BrancheGesundheitswesen

494.8 0.22

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

493.4

Max

497.4

Schlüsselkennzahlen
By Trading Economics
Einkommen	57M 483M
Verkäufe	-621M 3B
KGV Branchendurchschnitt	35.968 49.701
Dividendenrendite	1.07
Gewinnspanne	16.345
Angestellte	20,000
EBITDA	-181M 822M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+37.24% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	1.07% 2.39%
Nächstes Ergebnis	22. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-6B 33B
Vorheriger Eröffnungskurs	494.58
Vorheriger Schlusskurs	494.8

Nachrichtenstimmung

By Acuity

14%

86%

17 / 345 Ranking in Healthcare

Lonza Group AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Lonza Group AG Prognose

Kursziel

By TipRanks

37.24% Vorteil

12-Monats-Prognose

Durchschnitt 676.33 CHF 37.24%

Hoch 762 CHF

Tief 630 CHF

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Lonza Group AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lonza Group AG – Dist abgegeben haben.

Stimmung

By Acuity

17 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Andere Aktien aus dem Sektor

NOVN.CH

Novartis AG

119.52

↑ +0.02%

Lonza Group AG

Übersicht

Veränderung der Aktienkurses

Schlüsselkennzahlen

Empfehlungen

Dividenden

Marktstatistiken

Nachrichtenstimmung

Lonza Group AG Chart

Ähnliche Nachrichten

Peer-Vergleich

Lonza Group AG Prognose

Kursziel

Rating-Konsens

Stimmung

Finanzen

Über Lonza Group AG

Andere Aktien aus dem Sektor